247 related articles for article (PubMed ID: 22592586)
1. Time to initiate antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis treatment in HIV-infected patients: results from the TIME study.
Manosuthi W; Mankatitham W; Lueangniyomkul A; Thongyen S; Likanonsakul S; Suwanvattana P; Thawornwan U; Suntisuklappon B; Nilkamhang S; Sungkanuparph S;
J Acquir Immune Defic Syndr; 2012 Aug; 60(4):377-83. PubMed ID: 22592586
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Antiretroviral Therapy Initiated One Week after Tuberculosis Therapy in Patients with CD4 Counts < 200 Cells/μL: TB-HAART Study, a Randomized Clinical Trial.
Amogne W; Aderaye G; Habtewold A; Yimer G; Makonnen E; Worku A; Sonnerborg A; Aklillu E; Lindquist L
PLoS One; 2015; 10(5):e0122587. PubMed ID: 25966339
[TBL] [Abstract][Full Text] [Related]
3. The Effect of Early Initiation of Antiretroviral Therapy in TB/HIV-Coinfected Patients: A Systematic Review and Meta-Analysis.
Abay SM; Deribe K; Reda AA; Biadgilign S; Datiko D; Assefa T; Todd M; Deribew A
J Int Assoc Provid AIDS Care; 2015; 14(6):560-70. PubMed ID: 26289343
[TBL] [Abstract][Full Text] [Related]
4. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis.
Blanc FX; Sok T; Laureillard D; Borand L; Rekacewicz C; Nerrienet E; Madec Y; Marcy O; Chan S; Prak N; Kim C; Lak KK; Hak C; Dim B; Sin CI; Sun S; Guillard B; Sar B; Vong S; Fernandez M; Fox L; Delfraissy JF; Goldfeld AE;
N Engl J Med; 2011 Oct; 365(16):1471-81. PubMed ID: 22010913
[TBL] [Abstract][Full Text] [Related]
5. Integration of antiretroviral therapy with tuberculosis treatment.
Abdool Karim SS; Naidoo K; Grobler A; Padayatchi N; Baxter C; Gray AL; Gengiah T; Gengiah S; Naidoo A; Jithoo N; Nair G; El-Sadr WM; Friedland G; Abdool Karim Q
N Engl J Med; 2011 Oct; 365(16):1492-501. PubMed ID: 22010915
[TBL] [Abstract][Full Text] [Related]
6. Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trial.
Mfinanga SG; Kirenga BJ; Chanda DM; Mutayoba B; Mthiyane T; Yimer G; Ezechi O; Connolly C; Kapotwe V; Muwonge C; Massaga J; Sinkala E; Kohi W; Lyantumba L; Nyakoojo G; Luwaga H; Doulla B; Mzyece J; Kapata N; Vahedi M; Mwaba P; Egwaga S; Adatu F; Pym A; Joloba M; Rustomjee R; Zumla A; Onyebujoh P
Lancet Infect Dis; 2014 Jul; 14(7):563-71. PubMed ID: 24810491
[TBL] [Abstract][Full Text] [Related]
7. Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a systematic review and meta-analysis.
Jiang HY; Zhang MN; Chen HJ; Yang Y; Deng M; Ruan B
Int J Infect Dis; 2014 Aug; 25():130-5. PubMed ID: 24911886
[TBL] [Abstract][Full Text] [Related]
8. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis.
Havlir DV; Kendall MA; Ive P; Kumwenda J; Swindells S; Qasba SS; Luetkemeyer AF; Hogg E; Rooney JF; Wu X; Hosseinipour MC; Lalloo U; Veloso VG; Some FF; Kumarasamy N; Padayatchi N; Santos BR; Reid S; Hakim J; Mohapi L; Mugyenyi P; Sanchez J; Lama JR; Pape JW; Sanchez A; Asmelash A; Moko E; Sawe F; Andersen J; Sanne I;
N Engl J Med; 2011 Oct; 365(16):1482-91. PubMed ID: 22010914
[TBL] [Abstract][Full Text] [Related]
9. Initiation of antiretroviral therapy in HIV-infected tuberculosis patients in rural Kenya: an observational study.
Stockdale AJ; Nkuranga J; Török ME; Faragher B; Lalloo DG
Trop Med Int Health; 2013 Jul; 18(7):907-14. PubMed ID: 23590229
[TBL] [Abstract][Full Text] [Related]
10. Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1-Infected Patients Starting Efavirenz, Lopinavir-Ritonavir, or Atazanavir-Ritonavir Plus Tenofovir/Emtricitabine: Final 48-Week Results (The Advanz-3 Trial).
Miro JM; Manzardo C; Ferrer E; Loncà M; Guardo AC; Podzamczer D; Domingo P; Curran A; Clotet B; Cruceta A; Lozano F; Pérez I; Plana M; Gatell JM;
J Acquir Immune Defic Syndr; 2015 Jun; 69(2):206-15. PubMed ID: 25831464
[TBL] [Abstract][Full Text] [Related]
11. Early versus delayed initiation of antiretroviral therapy for Indian HIV-Infected individuals with tuberculosis on antituberculosis treatment.
Sinha S; Shekhar RC; Singh G; Shah N; Ahmad H; Kumar N; Sharma SK; Samantaray JC; Ranjan S; Ekka M; Sreenivas V; Mitsuyasu RT
BMC Infect Dis; 2012 Jul; 12():168. PubMed ID: 22846195
[TBL] [Abstract][Full Text] [Related]
12. Integration and task shifting for TB/HIV care and treatment in highly resource-scarce settings: one size may not fit all.
Van Rie A; Patel MR; Nana M; Vanden Driessche K; Tabala M; Yotebieng M; Behets F
J Acquir Immune Defic Syndr; 2014 Mar; 65(3):e110-7. PubMed ID: 24091692
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of the interval between the initiation of antiretroviral therapy and the initiation of anti-tuberculosis treatment in HIV/tuberculosis-coinfected patients: results from the TREAT Asia HIV Observational Database.
Han SH; Zhou J; Lee MP; Zhao H; Chen YM; Kumarasamy N; Pujari S; Lee C; Omar SF; Ditangco R; Phanuphak N; Kiertiburanakul S; Chaiwarith R; Merati TP; Yunihastuti E; Tanuma J; Saphonn V; Sohn AH; Choi JY;
HIV Med; 2014 Feb; 15(2):77-85. PubMed ID: 23980589
[TBL] [Abstract][Full Text] [Related]
14. Initiation of antiretroviral therapy in advanced AIDS with active tuberculosis: clinical experiences from Thailand.
Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Vibhagool A
J Infect; 2006 Mar; 52(3):188-94. PubMed ID: 15992932
[TBL] [Abstract][Full Text] [Related]
15. Tenofovir DF/emtricitabine and efavirenz combination therapy for HIV infection in patients treated for tuberculosis: the ANRS 129 BKVIR trial.
Lortholary O; Roussillon C; Boucherie C; Padoin C; Chaix ML; Breton G; Rami A; Veziris N; Patey O; Caumes E; May T; Molina JM; Robert J; Tod M; Fagard C; Chêne G;
J Antimicrob Chemother; 2016 Mar; 71(3):783-93. PubMed ID: 26679250
[TBL] [Abstract][Full Text] [Related]
16. Delayed antiretroviral therapy despite integrated treatment for tuberculosis and HIV infection.
Patel MR; Nana M; Yotebieng M; Tabala M; Behets F; Van Rie A
Int J Tuberc Lung Dis; 2014 Jun; 18(6):694-9. PubMed ID: 24903941
[TBL] [Abstract][Full Text] [Related]
17. [Impact of etiotropic therapy on the immune status of patients with HIV infection and tuberculosis].
Zimina VN; Kravchenko AV
Ter Arkh; 2015; 87(11):37-41. PubMed ID: 26821414
[TBL] [Abstract][Full Text] [Related]
18. Optimal Timing of Antiretroviral Therapy Initiation for HIV-Infected Adults With Newly Diagnosed Pulmonary Tuberculosis: A Systematic Review and Meta-analysis.
Uthman OA; Okwundu C; Gbenga K; Volmink J; Dowdy D; Zumla A; Nachega JB
Ann Intern Med; 2015 Jul; 163(1):32-9. PubMed ID: 26148280
[TBL] [Abstract][Full Text] [Related]
19. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
[TBL] [Abstract][Full Text] [Related]
20. The impact of HAART initiation timing on HIV-TB co-infected patients, a retrospective cohort study.
Yang CH; Chen KJ; Tsai JJ; Lin YH; Cheng SH; Wang KF; Chiou HY
BMC Infect Dis; 2014 Jun; 14():304. PubMed ID: 24897928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
